CTRI/2017/03/008202招募中4 期
A 6 week prospective open label comparative study of efficacy and safety of vilazodone and fluoxetine in major depressive disorder
Mysore medical college and research institute0 个研究点目标入组 72 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •subjects diagnosed with major depressive disorder, first episode (according to DSM -V criteria) or recurrent episodes.
- •Age: 18-65 years.
- •Both sexes.
- •Subjects who give informed consent.
排除标准
- •Severe depressive episode with suicidal/poor insight subject who is unable to give informed consent.
- •Subjects with any serious concurrent medical and psychiatric illness.
- •Presence of organic brain syndromes including delirium and dementia.
研究者
相似试验
尚未招募
不适用
Comparison of Moxifloxacin plus Dexamethasone eye drops treatment for 6-weeks vs 2-weeks in patients with eye operation.CTRI/2019/02/017692Santhiram Medical College and General Hospital
进行中（未招募）
不适用
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE) - PALATPrimary Nocturnal EnuresisMedDRA version: 6.1Level: LLTClassification code 10029453EUCTR2004-000593-32-SEFerring Pharmaceuticals A/S200
进行中（未招募）
1 期
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)Primary Nocturnal EnuresisMedDRA version: 6.1 Level: low Classification code 10029453EUCTR2004-000593-32-GBFerring Pharmaceuticals A/S200
进行中（未招募）
不适用
A 6-week open label cross-over study with 2 different daily doses of Minirin oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)Primary Nocturnal EnuresisMedDRA version: 6.1Level: lowClassification code 10029453EUCTR2004-000593-32-DEFerring Arzneimittel GmbH200
进行中（未招募）
不适用
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE) - PALATPrimary Nocturnal EnuresisMedDRA version: 6.1Level: LLTClassification code 10029453EUCTR2004-000593-32-FIFerring Pharmaceuticals A/S200